"MarketWatch San Francisco May 19," Beijing Time May 20 morning, credit rating agency Fitch announced that the heart medical equipment manufacturers: Boston Science Company (BSX) credit Outlook rating from "stable" to "expected to rise", citing the company's core business continued to improve. Fitch rated Boston Science's debt as "bb+". Fitch said in a statement: "The reason for the adjustment of the Outlook rating is that the Boston science of the drug-eluting stent business has stabilized and heart rhythm management business resumed growth." "The Boston science has repaid about $1.3 billion trillion in debt over the past four quarters," Fitch said. Boston Science's shares on the New York Stock Exchange rose 10 cents to $8.93, or 1.13%, as of Tuesday 12:43 (Beijing time Wednesday 0:43 A.M.).
The content source of this page is from Internet, which doesn't represent Alibaba Cloud's opinion;
products and services mentioned on that page don't have any relationship with Alibaba Cloud. If the
content of the page makes you feel confusing, please write us an email, we will handle the problem
within 5 days after receiving your email.
If you find any instances of plagiarism from the community, please send an email to:
info-contact@alibabacloud.com
and provide relevant evidence. A staff member will contact you within 5 working days.
